Duke Capital Limited has successfully exited its investment in Fairmed Healthcare AG, a Switzerland-based provider of pharmaceuticals in various EU countries. The headline cash consideration of €11.4 million provides Duke with additional liquidity for new deployments into its pipeline of long-established, profitable businesses. This marks the seventh exit for Duke, delivering its sixth profitable exit, and is at the upper end of the expected rate of return for Duke with no equity participation. Duke's financing solution enabled Fairmed's management team to retain its minority equity stake while receiving the capital to support the expansion of its product portfolio.
The exit was facilitated by Fairmed's majority owner, Strides Pharma Global Pte Ltd, a fully owned subsidiary of Strides Pharma Science Limited. Neil Johnson, CEO of Duke Capital, expressed pride in supporting Fairmed during a crucial time in the development of its product portfolio, empowering its management team to achieve their strategic objectives without burdening the business with loss of control or refinancing risk. Duke looks forward to continuing to deploy capital into other promising opportunities.
Duke Capital is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt. Since 2017, Duke has provided unique long-term financing, eliminating re-financing risk and the necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business. Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles.